The Experts below are selected from a list of 20298 Experts worldwide ranked by ideXlab platform
Paul M. Carvey - One of the best experts on this subject based on the ideXlab platform.
-
Rapid approach to the quantitative determination of Topiramate (2,3:4,5-bis-O-(1-methylethylidene)-β-D-fructopyranose sulfamate) in human plasma by liquid–liquid extraction and flow-injection negative-ion electrospray mass spectrometry
Rapid Communications in Mass Spectrometry, 1999Co-Authors: Su Chen, Paul M. CarveyAbstract:Topiramate, a sulfamate-substituted monosaccharide (2,3:4,5-bis-O-(1-methylethylidene)-β-D-fructopyranose sulfamate), is a new antiepileptic drug, which has been approved for adjunctive therapy in adult patients with partial-onset seizures. Liquid-liquid extraction followed by flow-injection negative-ion electrospray mass spectrometry was evaluated as a means for the quantitative analysis of Topiramate in human plasma. Prednisone (1,4-pregnadiene-17-α,21-diol-3,11,20-trione [15 µg/mL]) was used as the internal standard because its solubility and molecular weight are similar to those of Topiramate. Calibration curves for Topiramate were linear over a range of 1 to 30 µg/mL plasma (signal-to-noise ratio >4) and were highly reliable (r2 = 0.994). This approach offers several advantages: (i) the extraction of Topiramate from human plasma using chloroform is simple and reproducible; (ii) the quantitative determination of Topiramate, in the presence of an internal standard, by flow-injection negative-ion electrospray mass spectrometry with selected-ion recording, is rapid and accurate and does not require chromatographic separation; (iii) the assay possesses adequate sensitivity (2–25 µg/mL) for the quantitative analysis of Topiramate in plasma from patients. Copyright © 1999 John Wiley & Sons, Ltd.
-
rapid approach to the quantitative determination of Topiramate 2 3 4 5 bis o 1 methylethylidene β d fructopyranose sulfamate in human plasma by liquid liquid extraction and flow injection negative ion electrospray mass spectrometry
Rapid Communications in Mass Spectrometry, 1999Co-Authors: Su Chen, Paul M. CarveyAbstract:Topiramate, a sulfamate-substituted monosaccharide (2,3:4,5-bis-O-(1-methylethylidene)-β-D-fructopyranose sulfamate), is a new antiepileptic drug, which has been approved for adjunctive therapy in adult patients with partial-onset seizures. Liquid-liquid extraction followed by flow-injection negative-ion electrospray mass spectrometry was evaluated as a means for the quantitative analysis of Topiramate in human plasma. Prednisone (1,4-pregnadiene-17-α,21-diol-3,11,20-trione [15 µg/mL]) was used as the internal standard because its solubility and molecular weight are similar to those of Topiramate. Calibration curves for Topiramate were linear over a range of 1 to 30 µg/mL plasma (signal-to-noise ratio >4) and were highly reliable (r2 = 0.994). This approach offers several advantages: (i) the extraction of Topiramate from human plasma using chloroform is simple and reproducible; (ii) the quantitative determination of Topiramate, in the presence of an internal standard, by flow-injection negative-ion electrospray mass spectrometry with selected-ion recording, is rapid and accurate and does not require chromatographic separation; (iii) the assay possesses adequate sensitivity (2–25 µg/mL) for the quantitative analysis of Topiramate in plasma from patients. Copyright © 1999 John Wiley & Sons, Ltd.
Su Chen - One of the best experts on this subject based on the ideXlab platform.
-
Rapid approach to the quantitative determination of Topiramate (2,3:4,5-bis-O-(1-methylethylidene)-β-D-fructopyranose sulfamate) in human plasma by liquid–liquid extraction and flow-injection negative-ion electrospray mass spectrometry
Rapid Communications in Mass Spectrometry, 1999Co-Authors: Su Chen, Paul M. CarveyAbstract:Topiramate, a sulfamate-substituted monosaccharide (2,3:4,5-bis-O-(1-methylethylidene)-β-D-fructopyranose sulfamate), is a new antiepileptic drug, which has been approved for adjunctive therapy in adult patients with partial-onset seizures. Liquid-liquid extraction followed by flow-injection negative-ion electrospray mass spectrometry was evaluated as a means for the quantitative analysis of Topiramate in human plasma. Prednisone (1,4-pregnadiene-17-α,21-diol-3,11,20-trione [15 µg/mL]) was used as the internal standard because its solubility and molecular weight are similar to those of Topiramate. Calibration curves for Topiramate were linear over a range of 1 to 30 µg/mL plasma (signal-to-noise ratio >4) and were highly reliable (r2 = 0.994). This approach offers several advantages: (i) the extraction of Topiramate from human plasma using chloroform is simple and reproducible; (ii) the quantitative determination of Topiramate, in the presence of an internal standard, by flow-injection negative-ion electrospray mass spectrometry with selected-ion recording, is rapid and accurate and does not require chromatographic separation; (iii) the assay possesses adequate sensitivity (2–25 µg/mL) for the quantitative analysis of Topiramate in plasma from patients. Copyright © 1999 John Wiley & Sons, Ltd.
-
rapid approach to the quantitative determination of Topiramate 2 3 4 5 bis o 1 methylethylidene β d fructopyranose sulfamate in human plasma by liquid liquid extraction and flow injection negative ion electrospray mass spectrometry
Rapid Communications in Mass Spectrometry, 1999Co-Authors: Su Chen, Paul M. CarveyAbstract:Topiramate, a sulfamate-substituted monosaccharide (2,3:4,5-bis-O-(1-methylethylidene)-β-D-fructopyranose sulfamate), is a new antiepileptic drug, which has been approved for adjunctive therapy in adult patients with partial-onset seizures. Liquid-liquid extraction followed by flow-injection negative-ion electrospray mass spectrometry was evaluated as a means for the quantitative analysis of Topiramate in human plasma. Prednisone (1,4-pregnadiene-17-α,21-diol-3,11,20-trione [15 µg/mL]) was used as the internal standard because its solubility and molecular weight are similar to those of Topiramate. Calibration curves for Topiramate were linear over a range of 1 to 30 µg/mL plasma (signal-to-noise ratio >4) and were highly reliable (r2 = 0.994). This approach offers several advantages: (i) the extraction of Topiramate from human plasma using chloroform is simple and reproducible; (ii) the quantitative determination of Topiramate, in the presence of an internal standard, by flow-injection negative-ion electrospray mass spectrometry with selected-ion recording, is rapid and accurate and does not require chromatographic separation; (iii) the assay possesses adequate sensitivity (2–25 µg/mL) for the quantitative analysis of Topiramate in plasma from patients. Copyright © 1999 John Wiley & Sons, Ltd.
Tania P Markovic - One of the best experts on this subject based on the ideXlab platform.
-
management of obesity and cardiometabolic risk role of phentermine extended release Topiramate
Diabetes Metabolic Syndrome and Obesity: Targets and Therapy, 2014Co-Authors: Arianne N Sweeting, Eddy Tabet, Ian D. Caterson, Tania P MarkovicAbstract:The US Food and Drug Administration (FDA) recently approved lorcaserin and the combination of phentermine and extended release Topiramate (phentermine/Topiramate ER) for the treatment of obesity in conjunction with a lifestyle intervention, expanding the therapeutic options for long-term obesity pharmacotherapy, which was previously limited to orlistat. Combination phentermine/Topiramate ER is associated with greater weight loss compared to its constituent monotherapy, with a more favorable adverse effect profile. Phentermine/Topiramate ER also appears to have beneficial effects on cardiometabolic risk, although longer-term cardiovascular safety data are required. While there are no head-to-head studies among the currently available obesity pharmacotherapy agents, phentermine/Topiramate ER appears to have a superior weight loss profile. This review will discuss the epidemiology, natural history, and cardiometabolic risk associated with obesity, provide an overview on current obesity pharmacotherapy, and summarize the recent clinical efficacy and safety data underpinning the FDA’s approval of both phentermine/Topiramate ER and lorcaserin as pharmacotherapy for a long-term obesity intervention.
-
Management of obesity and cardiometabolic risk - role of phentermine/extended release Topiramate.
Diabetes Metabolic Syndrome and Obesity: Targets and Therapy, 2014Co-Authors: Arianne N Sweeting, Eddy Tabet, Ian D. Caterson, Tania P MarkovicAbstract:The US Food and Drug Administration (FDA) recently approved lorcaserin and the combination of phentermine and extended release Topiramate (phentermine/Topiramate ER) for the treatment of obesity in conjunction with a lifestyle intervention, expanding the therapeutic options for long-term obesity pharmacotherapy, which was previously limited to orlistat. Combination phentermine/Topiramate ER is associated with greater weight loss compared to its constituent monotherapy, with a more favorable adverse effect profile. Phentermine/Topiramate ER also appears to have beneficial effects on cardiometabolic risk, although longer-term cardiovascular safety data are required. While there are no head-to-head studies among the currently available obesity pharmacotherapy agents, phentermine/Topiramate ER appears to have a superior weight loss profile. This review will discuss the epidemiology, natural history, and cardiometabolic risk associated with obesity, provide an overview on current obesity pharmacotherapy, and summarize the recent clinical efficacy and safety data underpinning the FDA’s approval of both phentermine/Topiramate ER and lorcaserin as pharmacotherapy for a long-term obesity intervention.
Salvatore Striano - One of the best experts on this subject based on the ideXlab platform.
-
Topiramate-associated worsening symptoms in a patient with familial hemiplegic migraine.
Journal of the neurological sciences, 2008Co-Authors: Pasquale Striano, Federico Zara, Filippo Maria Santorelli, Salvatore StrianoAbstract:Topiramate has been shown to be highly effective for preventive treatment of migraine and its use has been significantly increased in the last few years. However, around 10% of migraineurs develop a worsening of their symptoms while on Topiramate. We report a 33-year-old woman with familial hemiplegic migraine (FHM) who experienced worsening of her symptoms following repeated Topiramate intake. Withdrawal of the drug rapidly constantly induced resolution of the symptoms. This is the first report of Topiramate-associated worsening symptoms in FHM. It is important to be aware of this phenomenon, as Topiramate is worldwide-used drug for migraine treatment.
-
Short communication Topiramate-associated worsening symptoms in a patient with familial hemiplegic migraine
2008Co-Authors: Pasquale Striano, Federico Zara, Filippo Maria Santorelli, Salvatore StrianoAbstract:Topiramate has been shown to be highly effective for preventive treatment of migraine and its use has been significantly increased in the last few years. However, around 10% of migraineurs develop a worsening of their symptoms while on Topiramate. We report a 33-year-old woman with familial hemiplegic migraine (FHM) who experienced worsening of her symptoms following repeated Topiramate intake. Withdrawal of the drug rapidly constantly induced resolution of the symptoms. This is the first report of Topiramate-associated worsening symptoms in FHM. It is important to be aware of this phenomenon, as Topiramate is worldwide-used drug for migraine treatment. © 2008 Elsevier B.V. All rights reserved.
Arianne N Sweeting - One of the best experts on this subject based on the ideXlab platform.
-
management of obesity and cardiometabolic risk role of phentermine extended release Topiramate
Diabetes Metabolic Syndrome and Obesity: Targets and Therapy, 2014Co-Authors: Arianne N Sweeting, Eddy Tabet, Ian D. Caterson, Tania P MarkovicAbstract:The US Food and Drug Administration (FDA) recently approved lorcaserin and the combination of phentermine and extended release Topiramate (phentermine/Topiramate ER) for the treatment of obesity in conjunction with a lifestyle intervention, expanding the therapeutic options for long-term obesity pharmacotherapy, which was previously limited to orlistat. Combination phentermine/Topiramate ER is associated with greater weight loss compared to its constituent monotherapy, with a more favorable adverse effect profile. Phentermine/Topiramate ER also appears to have beneficial effects on cardiometabolic risk, although longer-term cardiovascular safety data are required. While there are no head-to-head studies among the currently available obesity pharmacotherapy agents, phentermine/Topiramate ER appears to have a superior weight loss profile. This review will discuss the epidemiology, natural history, and cardiometabolic risk associated with obesity, provide an overview on current obesity pharmacotherapy, and summarize the recent clinical efficacy and safety data underpinning the FDA’s approval of both phentermine/Topiramate ER and lorcaserin as pharmacotherapy for a long-term obesity intervention.
-
Management of obesity and cardiometabolic risk - role of phentermine/extended release Topiramate.
Diabetes Metabolic Syndrome and Obesity: Targets and Therapy, 2014Co-Authors: Arianne N Sweeting, Eddy Tabet, Ian D. Caterson, Tania P MarkovicAbstract:The US Food and Drug Administration (FDA) recently approved lorcaserin and the combination of phentermine and extended release Topiramate (phentermine/Topiramate ER) for the treatment of obesity in conjunction with a lifestyle intervention, expanding the therapeutic options for long-term obesity pharmacotherapy, which was previously limited to orlistat. Combination phentermine/Topiramate ER is associated with greater weight loss compared to its constituent monotherapy, with a more favorable adverse effect profile. Phentermine/Topiramate ER also appears to have beneficial effects on cardiometabolic risk, although longer-term cardiovascular safety data are required. While there are no head-to-head studies among the currently available obesity pharmacotherapy agents, phentermine/Topiramate ER appears to have a superior weight loss profile. This review will discuss the epidemiology, natural history, and cardiometabolic risk associated with obesity, provide an overview on current obesity pharmacotherapy, and summarize the recent clinical efficacy and safety data underpinning the FDA’s approval of both phentermine/Topiramate ER and lorcaserin as pharmacotherapy for a long-term obesity intervention.
